MOEXIPRIL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H34N2O7
Molecular Weight	498.5681
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(OC)=C(OC)C=C3C[C@H]2C(O)=O

InChI

InChIKey=UWWDHYUMIORJTA-HSQYWUDLSA-N

InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C27H34N2O7
Molecular Weight	498.5681
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020312s033lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/14728069https://www.ncbi.nlm.nih.gov/pubmed/15286086
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16620521 | https://www.ncbi.nlm.nih.gov/pubmed/26076923 | https://www.ncbi.nlm.nih.gov/pubmed/9257913 | https://www.ncbi.nlm.nih.gov/pubmed/9079232

Moexiprilat is the pharmacologically active metabolite of Moexipril. Formation of Moexiprilat is caused by hydrolysis of a Moexipril’s ethyl ester group. Moexiprilat competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilatation. This agent also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis. Moexiprilat showed an extended duration of action owing to a long terminal pharmacokinetic half-life and produced a persistent ACE inhibition.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 94 Target ID: CHEMBL1808 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020312s033lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/14728069	Inhibitor 8504		2.6 nM [IC50]
Angiotensin-converting enzyme 94 Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26076923	Inhibitor 8504		2.6 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: https://www.drugs.com/pro/moexipril.html	Primary		Approved 8583	Moexipril Approved Use Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). Launch Date 1995
Hypertension 575 Sources: https://www.drugs.com/pro/moexipril.html	Primary		Natural Metabolite	Moexipril Approved Use Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). Launch Date 1995

C_max

Value	Dose	Analyte	Population
16 ng/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
48 ng/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
154 ng/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
194 ng/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
98 ng × h/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
136 ng × h/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
328 ng × h/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
320 ng × h/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
10 h EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOEXIPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
30% EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOEXIPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
30% EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOEXIPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11854821/	unhealthy, 55.4 Health Status: unhealthy Age Group: 55.4 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/11854821/	Sources: https://pubmed.ncbi.nlm.nih.gov/11854821/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CES1 45 CES2 33 PEPT1 60 PEPT2 37

Drug as victim

Target	Modality	Activity	Metabolite
CES2 33	substrate 4014 Sources: https://www.nature.com/articles/tpj201542	no
CES1 45	substrate 4014 Sources: https://www.nature.com/articles/tpj201542	yes
PEPT1 60	substrate 4014 Sources: https://www.tandfonline.com/doi/abs/10.1517/17425250903042292	yes	MOEXIPRIL 4
PEPT2 37	substrate 4014 Sources: https://www.tandfonline.com/doi/abs/10.1517/17425250903042292	yes	MOEXIPRIL 4

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L1IVG
ABI Chem	AC1Q5QO2
Alfa Chemistry	103775-14-0	https://www.alfa-chemistry.com/cas_103775-14-0.htm
Alfa Chemistry	AP103775140	https://reagents.alfa-chemistry.com/product/moexipril-related-compound-a-cas-103775-14-0-948.html
BioSynth	J-001037	https://www.biosynth.com/en/products/all-products/products/J-001037.html
BOC Sciences	103775-14-0
Chemieliva Pharmaceutical Co., Ltd	PBCM1057676
ChemTik	CTK8E8826
DC Chemicals	DC36859	http://www.dcchemicals.com//product_show-Moexiprilat.html
eMolecules	45917802
MuseChem	R044673	https://www.musechem.com/product/R044673.html
NovoSeek	55331
Smolecule	S535918	http://www.smolecule.com/products/s535918
Smolecule	S793772	https://www.smolecule.com/products/s793772
THE BioTek	bt-276722	https://www.thebiotek.com/product/inhibitors/bt-276722
Toronto Research Chemicals	M485320
Toronto Research Chemicals	M485360
Tractus	RT-013928
Wonderchem	WD04LWO
ZINC	ZINC000003789196	http://zinc15.docking.org/substances/ZINC000003789196

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
Spectrophotometric method for simultaneous estimation of atenolol in combination with losartan potassium and hydrochlorothiazide in bulk and tablet formulation.	2010-10	21180476
Anti-hypertensive drugs have different effects on ventricular hypertrophy regression.	2010-07	20668631
Determination of antihypertensive drug moexipril hydrochloride based on the enhancement effect of sodium dodecyl sulfate at carbon paste electrode.	2010-04-15	20188882
Identification and determination of antihypertonics from the group of angiotensin-convertase inhibitors by densitometric method in comparition with HPLC method.	2010-04-08	20369790
Adverse drug reaction monitoring with angiotensin converting enzyme inhibitors: A prospective, randomized, open-label, comparative study.	2010-02	20606833
Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.	2010-02	19255851
Inhibition of central angiotensin-converting enzyme with enalapril protects the brain from ischemia/reperfusion injury in normotensive rat.	2010	22615591
Drugs associated with more suicidal ideations are also associated with more suicide attempts.	2009-10-02	19798416
Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.	2009-08	20676275
Stabilization of quinapril by incorporating hydrogen bonding interactions.	2009-07	20502545
Impact of statins and ACE inhibitors on mortality after COPD exacerbations.	2009-06-03	19493329
[Preventive pharmacotherapy in arterial hypertension: problems of clinical assessment of drugs in women].	2009	19656111
The Effect of the Dried-Bonito Broth on Blood Pressure, 8-Hydroxydeoxyguanosine (8-OHdG), an Oxidative Stress Marker, and Emotional States in Elderly Subjects.	2008-11	19015752
Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited.	2008-11	18713951
The prince and the pauper. A tale of anticancer targeted agents.	2008-10-23	18947424
[Clinico-economical efficacy of angiotensin converting enzyme inhibitors in patients with arterial hypertension and ischemic heart disease].	2008	18729835
Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS.	2007-01	17266629
[Assessment of the effect of angiotensin converting enzyme inhibitor moexipril on the functional state of vascular wall in patients with I - III degree arterial hypertension].	2007	18260911
Moexipril and left ventricular hypertrophy.	2007	17583172
Monitoring the metabolism of moexipril to moexiprilat using high-performance liquid chromatography-electrospray ionization mass spectrometry.	2006-04	16620521
[Angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension. Possibilities of moexipril in the treatment of postmenopausal women].	2006	17159885
[Dynamics of left ventricular longitudinal function in patients with arterial hypertension during therapy with angiotensin converting enzyme inhibitor moexipril].	2006	17047618
[Moexipril and cardiovascular diseases in women: is there a reason for optimism?].	2006	16883271
[Hypotensive, organoprotective, and metabolic effects of Angiotensin converting enzyme inhibitor moexipril in women with postmenopausal syndrome].	2006	16858353
[Investigation of efficacy of cardiovascular drugs in women].	2006	16710266
[Comparative efficacy and safety of contemporary Angiotensin converting enzyme inhibitors moexipril and spirapril in women with postmenopausal metabolic syndrome].	2006	16474309
Subchronic exposure to high-dose ACE-inhibitor moexipril induces catalase activity in rat liver.	2005-12	16311918
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005-06	15962942
MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial.	2005-04-20	15823625
Regression of left ventricular hypertrophy with moexipril, an angiotensin-converting enzyme inhibitor, in hypertensive patients.	2005-01-22	15662286
[Assessment of antihypertensive efficacy of moexipril in metabolic syndrome].	2005	16353045
[Moexipril influence on quality of life in postmenopausal women with arterial hypertension].	2005	16320692
[The use of moexipril in postmenopausal women with hypertension and associated changes of bone mineral density].	2005	16091658
[Hemodynamic and anti-ischemic effects of moexipril in patients having postinfarction heart dysfunction and moderate left ventricular heart failure].	2005	15759492
The influence of relative humidity and temperature on stability of moexipril hydrochloride in solid phase.	2004-10-21	15493289
Pharmacological and clinical profile of moexipril: a concise review.	2004-08	15286086
[Hypertension in postmenopausal women: medical and social significance and results of therapy with moexipril.].	2004	15477782
Simultaneous determination of moexipril hydrochloride and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromatographic methods.	2003-10-15	14550868
Pharmacological profile and clinical use of moexipril.	2003-09	15030263
Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation.	2003-01	12602539
ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.	2003	14728069
Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril.	1998-09	9825188
Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors.	1998-06-10	9620109
Moexipril. A review of its use in the management of essential hypertension.	1998-06	9617599
Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide).	1998-05	9643274
Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats.	1997-09	9379124
Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients.	1996	8803515
Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring.	1995-03	7608310
Evidence for site-specific absorption of a novel ACE inhibitor.	1989-09	2554270

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Hypertension Initial dose: -Patients not receiving diuretic therapy: 7.5 mg orally once a day 1 hour before meals -Patients receiving diuretic therapy: 3.75 mg orally once a day 1 hour before meals Maintenance dose: 7.5 to 30 mg orally per day in 1 or 2 divided doses 1 hour before meals. Maximum dose: 60 mg/day

Route of Administration: Oral

In Vitro Use Guide

In vitro, moexiprilat (active diacid metabolite of moexipril) was a potent inhibitor of ACE in guinea pig serum as well as on purified ACE from rabbit lung with IC50 values of 2.6 and 4.9 nmol/l, respectively. Both, moexipril and moexiprilat inhibited the angiotensin I (ANG I)-induced contractions of rabbit aorta concentration-dependently.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:08:08 GMT 2025` Edited by `admin` on `Mon Mar 31 18:08:08 GMT 2025`
Record UNII	WT87C52TJZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOEXIPRIL

Official Name

English

RS-10085

Preferred Name

English

MOEXIPRIL [MI]

Common Name

English

3-ISOQUINOLINECARBOXYLIC ACID, 2-(2-((1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-, (3S-(2(R*(R*)),3R*))-

Common Name

English

moexipril [INN]

Common Name

English

(3S)-2-((2S)-N-((1S)-1-CARBOXY-3-PHENYLPROPYL)ALANYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-3-ISOQUINOLINECARBOXYLIC ACID, 2-ETHYL ESTER

Common Name

English

(3S)-2-((2S)-2-(((1S)-1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-3-ISOQUINOLINECARBOXYLIC ACID

Systematic Name

English

Moexipril [WHO-DD]

Common Name

English

MOEXIPRIL [VANDF]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C247